The FDA could decide whether to loosen rules around peptide production this week. Some telehealth players are already seeing dollar signs.

As regulators weigh whether pharmacies can legally compound wellness peptides, companies are preparing for a repeat of the GLP-1 boom—only this time with even murkier science.

The FDA could decide whether to loosen rules around peptide production this week. Some telehealth players are already seeing dollar signs.